1. Effect of instillation therapy on quality of life (Time Frame - During the study period approximately 12 months): Quality of life will be measured with validated questionnaires such as the ICIQ-OABqol
2. Effect of instillation therapy on sexuality (Time Frame - During the study period approximately 12 months): Sexuality will be measured with validated questionnaires such as the IIEF-EF (men) and the FSFI (women)
3. Effect of instillation therapy on lower urinary tract symptoms (Time Frame - During the study period approximately 12 months): Lower urinary tract symptoms will be measured with validated questionnaires such as the BPIC-SS, the ICIQ-MLUTS (men) and the ICIQ-FLUTS (women)
Secondary outcome:
1. Complications during instillation therapy (Time Frame - During the study period approximately 12 months): The frequency of all complications will be measured and will be subsequently classified based on the Clavien-Dindo classification
2. Discontinuation rate of instillation therapy (Time Frame - During the study period approximately 12 months)
Patients undergoing instillation therapy with BCG All patients that undergo therapy with BCG after diagnosis of non-muscle-invasive bladder cancer
Patients undergoing instillation therapy with Mitomycin C All patients that undergo therapy with Mitomycin C after diagnosis of non-muscle-invasive bladder cancer
